AMT-130 Four-Year Update Complicates a Stronger 36-Month Case

Company uniQure Event Type Long-Term Clinical Data Update Modality AAV Gene Therapy Asset Ifezuntirgene Inilparvovec (AMT-130) Target Huntingtin (HTT) Disease Area Huntington Disease Summary uniQure reported new 48-month data for ifezuntirgene inilparvovec, formerly AMT-130, in early manifest Huntington disease. Among 12 high-dose patients, cUHDRS decline…